| CAS: | 3778-73-2 | |||||||||||||||||||||||||||||
| 分子式: | C7H15Cl2N2O2P | |||||||||||||||||||||||||||||
| 分子量: | 261.09 | |||||||||||||||||||||||||||||
| 中文名称: |
| |||||||||||||||||||||||||||||
| 英文名称: |
| |||||||||||||||||||||||||||||
| 用途: | 抗癌药物。 |
| 货号 | 品牌 | 产品名称 | 规格 | 包装、参考价格 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| I812171 | MACKLIN | 异环磷酰胺 | 98% | 125元/1g; 438元/5g; 1599元/25g; | 咨询 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
储存:2~8°C 状态:白色或灰白色粉末 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| I796920 | MACKLIN | 异环磷酰胺 | 10mM in DMSO | 385元/1ml; | 咨询 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
储存:-20°C | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| I0713 | TCI | Ifosfamide | >95.0%(GC)(T) | 995元/1G; | 咨询 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
基本信息
技术规格
物性(参考值)
安全信息
相关法规
运输信息
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 608272 | J&K | Ifosfamide | 98%, 一种烷基化化疗药物, 具有广谱的抗肿瘤作用 | 562元/250MG; 1853元/1G; | 咨询 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
基本信息
产品描述 DNA/RNA Synthesis, 靶点(IC50 & Targe) DNA/RNA Synthesis 体外研究 Ifosfamide(50 mM)增加肝细胞中的CYP3A4,CYP2C8,CYP2C9蛋白水平,这提高了培养肝细胞自身的4-羟基化率。在表达CYP3A5和更广泛表达CYP3A4的肝细胞中,Ifosfamide只诱导CYP3A4的表达。[1] Ifosfamide在肝脏中通过细胞色素P450混合功能氧化酶代谢成为isofosforamide芥前药,活性烷基化化合物。在小细胞肺癌,小儿实体瘤,non-Hodgkin's和Hodgkin's淋巴瘤和卵巢癌中,Ifosfamide已经产生良好的反应率。[2]在稳定转染CYP2B1的MCF-7细胞中,Ifosfamide有高度细胞毒性,此细胞毒性可以明显被CYP2B1抑制剂metyrapone阻止,但对亲本肿瘤细胞和beta-半乳糖苷酶表达的MCF-7细胞无影响。[3] Ifosfamide和Zoledronic acid联用比单独用药在预防肿瘤复发,提高组织修复,增加骨形成(分析骨小梁结构)更有效。[4] 体内研究 在小鼠中,Ifosfamide(100毫克/千克,200毫克/公斤和400毫克/千克)腹膜内注射剂量依赖性地诱导膀胱湿重和Evans蓝外渗的增加。Ifosfamide揭示了小鼠中广泛膀胱炎特征,包括急性炎症和血管充血,水肿,出血和血纤维蛋白沉积,中性粒细胞浸润和上皮剥脱。Ifosfamide显示出对细胞质中诱导型一氧化氮合酶以及对苏木精和曙红染色强度和弥漫性坏死的强烈反应。[5] 参考文献 [1] Chang TK, et al. Cancer Res, 1997, 57(10), 1946-1954. [2] Dechant KL, et al. Drugs, 1991, 42(3), 428-467. [3] Chen L, et al. Cancer Res, 1996, 56(6), 1331-1340. [4] Heymann D, et al. Bone, 2005, 37(1), 74-86. [5] Ribeiro RA, et al. J Urol, 2002, 167(5), 2229-2234. 安全信息
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| C46135 | Alfa Aesar | Ifosfamide | 3193元/1g; 11758元/5g; | 咨询 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
基本信息 Ref# 分子式 分子量 GHS危害和防范说明 GHS符号 Hazard Statements Precautionary Statements 安全信息 危险等级 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| PHR3187 | Supelco | Ifosfamide | pharmaceutical secondary standard, certified reference material | 2472.95元/1 g; | 咨询 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
产品说明 一般描述 Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards 生化/生理作用 异环磷酰胺是一种氮芥类化合物,是环磷酰胺的结构异构体。 异环磷酰胺是一种前药,必须通过细胞色素P450转化为生物活性成分。 它在癌症化疗中可用作抗肿瘤药,但是异环磷酰胺比环磷酰胺更可能引起肾毒性。 分析说明 These secondary standards offer multi-traceability to the USP, EP and BP primary standards, where they are available. 其他说明 This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis. 附注 To see an example of a Certificate of Analysis for this material enter LRAA6959(changes by product) in the Documents slot below. This is an example certificate only and may not be the lot that you receive. 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| I4909 | Sigma-Aldrich | Ifosfamide | ≥98% | 2204.58元/1 G; 8648.59元/5 G; | 咨询 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
产品说明 包装 1, 5 g in glass bottle 生化/生理作用 异环磷酰胺是一种氮芥类化合物,是环磷酰胺的结构异构体。 异环磷酰胺是一种前药,必须通过细胞色素P450转化为生物活性成分。 它在癌症化疗中可用作抗肿瘤药,但是异环磷酰胺比环磷酰胺更可能引起肾毒性。 其他说明 Tandem Mass Spectrometry data independently generated by Scripps Center for Metabolomics is available to view or download in PDF. I4909.pdf Tested metabolites are featured on Scripps Center for Metabolomics METLIN Metabolite Database. To learn more, visit sigma.com/metlin. 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| I0060000 | Ifosfamide | European Pharmacopoeia (EP) Reference Standard | 1277.32元/ ; | 咨询 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
产品说明 一般描述 This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia. 生化/生理作用 异环磷酰胺是一种氮芥类化合物,是环磷酰胺的结构异构体。 异环磷酰胺是一种前药,必须通过细胞色素P450转化为生物活性成分。 它在癌症化疗中可用作抗肿瘤药,但是异环磷酰胺比环磷酰胺更可能引起肾毒性。 包装 Unit quantity: 50 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue. 注意 Please find SDS provided by EDQM here.. 其他说明 Sales restrictions may apply. 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 1336205 | USP | Ifosfamide | United States Pharmacopeia (USP) Reference Standard | 3231.47元/500 MG; | 咨询 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
产品说明 一般描述 This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia. 生化/生理作用 异环磷酰胺是一种氮芥类化合物,是环磷酰胺的结构异构体。 异环磷酰胺是一种前药,必须通过细胞色素P450转化为生物活性成分。 它在癌症化疗中可用作抗肿瘤药,但是异环磷酰胺比环磷酰胺更可能引起肾毒性。 分析说明 These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind. 其他说明 USP issued SDS can be found here. 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| BP759 | Ifosfamide | British Pharmacopoeia (BP) Reference Standard | 1861.35元/100 MG; | 咨询 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
产品说明 一般描述 This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia. 生化/生理作用 异环磷酰胺是一种氮芥类化合物,是环磷酰胺的结构异构体。 异环磷酰胺是一种前药,必须通过细胞色素P450转化为生物活性成分。 它在癌症化疗中可用作抗肿瘤药,但是异环磷酰胺比环磷酰胺更可能引起肾毒性。 包装 Unit quantity: 100 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity please visit British Pharmacopoeia 其他说明 Sales restrictions may apply. 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 036578 | Fluorochem | 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydrochloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorineoxide | 97% | 2750元/250mg; 6864元/1g; 20548元/5g; | 咨询 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
基本信息
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||